Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study

Ana Marques^{1

2

3}, Elise Macias^{4

5}, Bruno Pereira⁶, Elodie Durand^{4

5}, Carine Chassain^{4

5}, Tiphaine Vidal^{4

5}, Luc Defebvre⁷, Nicolas Carriere⁷, Valerie Fraix⁸, Elena Moro⁸, Stéphane Thobois^{9

10

11}, Elise Metereau^{9

10

11}, Graziella Mangone¹², Marie Vidailhet¹², Jean-Christophe Corvol¹², Stéphane Lehéricy¹³, Nicolas Menjot de Champfleur^{14

15}, Christian Geny¹⁶, Umberto Spampinato^{17

18}, Wassilios G Meissner^{17

19

20

21}, Solène Frismand²², Emmanuelle Schmitt²³, Anne Doé de Maindreville²⁴, Christophe Portefaix^{25

26}, Philippe Remy²⁷, Gilles Fénelon²⁷, Jean Luc Houeto^{28

29}, Olivier Colin³⁰, Olivier Rascol³¹, Patrice Peran³², Jean-Marie Bonny^{33

34}, Maria Livia Fantini^{4

5}, Franck Durif^{4

5}; R2* Study Group

Affiliations

¹ University Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France. ar_marques@chu-clermontferrand.fr.
² Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand University Hospital, Clermont-Ferrand, France. ar_marques@chu-clermontferrand.fr.
³ Neurology Department, Parkinson Expert Center, CHRU Gabriel Montpied, 63000, Clermont-Ferrand, France. ar_marques@chu-clermontferrand.fr.
⁴ University Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France.
⁵ Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
⁶ Clermont-Ferrand University Hospital, Biostatistics Unit (DRCI), Clermont-Ferrand, France.
⁷ Department of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172, University of Lille, Lille, France.
⁸ Université Grenoble Alpes, CHU de Grenoble, Service de Neurologie, Grenoble Institute of Neuroscience, and NS-PARK/FCRIN Network, Grenoble, France.
⁹ CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon, France.
¹⁰ Université Claude Bernard, Lyon I, Lyon, France.
¹¹ Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C and NS-PARK/FCRIN Network, Lyon, France.
¹² Département de Neurologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
¹³ Département de Neuroradiologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225; Hôpital Pitié-Salpêtrière, Paris, France.
¹⁴ Department of Neuroradiology, Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France.
¹⁵ I2FH, Institut d'Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, CHRU de Montpellier, Montpellier, France.
¹⁶ Department of Geriatrics and NS-PARK/FCRIN Network, Montpellier University Hospital, Montpellier University, Montpellier, France.
¹⁷ Service de Neurologie-Maladies Neurodégénératives and NS-PARK/FCRIN Network, CHU Bordeaux, 33000, Bordeaux, France.
¹⁸ INCIA-UMR 5287, Team P3TN, CNRS/Université de Bordeaux, Bordeaux, France.
¹⁹ Univ. Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, 33000, Bordeaux, France.
²⁰ Dept. Medicine, University of Otago, Christchurch, New Zealand.
²¹ New Zealand Brain Research Institute, Christchurch, New Zealand.
²² Department of Neurology and NS-PARK/FCRIN Network, Nancy University Hospital Center, Nancy, France.
²³ Department of Neuroradiology, Nancy University Hospital Center, Nancy, France.
²⁴ Department of Neurology and NS-PARK/FCRIN Network, Hôpital Maison Blanche, Reims, France.
²⁵ Department of Radiology, Hôpital Maison Blanche, Reims, France.
²⁶ CReSTIC Laboratory, University of Reims Champagne-Ardenne, Reims, France.
²⁷ Centre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor; AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne Université, Créteil, France.
²⁸ INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, Poitiers, France.
²⁹ CHU-Centre Expert Parkinson de Limoges, Limoges, France.
³⁰ INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, CH Brive la Gaillarde, Poitiers, France.
³¹ Centre Expert Parkinson, Départements de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, UMR 1214 TONIC, NeuroToul and NS-PARK/FCRIN Network, INSERM, CHU de Toulouse et Université de Toulouse3, Toulouse, France.
³² ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS, Toulouse, France.
³³ INRAE, UR QuaPA, 63122, Saint-Genès-Champanelle, France.
³⁴ Nuclear Magnetic Resonance Facility for Agronomy, Food and Health, AgroResonance, INRAE, 2018, Saint-Genès-Champanelle, France.

PMID: 37648911
DOI: 10.1007/s00415-023-11947-0

Multicenter Study

Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study

Ana Marques et al. J Neurol. 2023 Dec.

. 2023 Dec;270(12):6033-6043.

doi: 10.1007/s00415-023-11947-0. Epub 2023 Aug 31.

Authors

Affiliations

¹ University Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France. ar_marques@chu-clermontferrand.fr.
² Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand University Hospital, Clermont-Ferrand, France. ar_marques@chu-clermontferrand.fr.
³ Neurology Department, Parkinson Expert Center, CHRU Gabriel Montpied, 63000, Clermont-Ferrand, France. ar_marques@chu-clermontferrand.fr.
⁴ University Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute Pascal, Clermont-Ferrand, France.
⁵ Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
⁶ Clermont-Ferrand University Hospital, Biostatistics Unit (DRCI), Clermont-Ferrand, France.
⁷ Department of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172, University of Lille, Lille, France.
⁸ Université Grenoble Alpes, CHU de Grenoble, Service de Neurologie, Grenoble Institute of Neuroscience, and NS-PARK/FCRIN Network, Grenoble, France.
⁹ CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon, France.
¹⁰ Université Claude Bernard, Lyon I, Lyon, France.
¹¹ Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C and NS-PARK/FCRIN Network, Lyon, France.
¹² Département de Neurologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
¹³ Département de Neuroradiologie and NS-PARK/FCRIN Network, Sorbonne Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225; Hôpital Pitié-Salpêtrière, Paris, France.
¹⁴ Department of Neuroradiology, Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France.
¹⁵ I2FH, Institut d'Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac, CHRU de Montpellier, Montpellier, France.
¹⁶ Department of Geriatrics and NS-PARK/FCRIN Network, Montpellier University Hospital, Montpellier University, Montpellier, France.
¹⁷ Service de Neurologie-Maladies Neurodégénératives and NS-PARK/FCRIN Network, CHU Bordeaux, 33000, Bordeaux, France.
¹⁸ INCIA-UMR 5287, Team P3TN, CNRS/Université de Bordeaux, Bordeaux, France.
¹⁹ Univ. Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, 33000, Bordeaux, France.
²⁰ Dept. Medicine, University of Otago, Christchurch, New Zealand.
²¹ New Zealand Brain Research Institute, Christchurch, New Zealand.
²² Department of Neurology and NS-PARK/FCRIN Network, Nancy University Hospital Center, Nancy, France.
²³ Department of Neuroradiology, Nancy University Hospital Center, Nancy, France.
²⁴ Department of Neurology and NS-PARK/FCRIN Network, Hôpital Maison Blanche, Reims, France.
²⁵ Department of Radiology, Hôpital Maison Blanche, Reims, France.
²⁶ CReSTIC Laboratory, University of Reims Champagne-Ardenne, Reims, France.
²⁷ Centre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor; AP-HP et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé, Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne Université, Créteil, France.
²⁸ INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, Poitiers, France.
²⁹ CHU-Centre Expert Parkinson de Limoges, Limoges, France.
³⁰ INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, CH Brive la Gaillarde, Poitiers, France.
³¹ Centre Expert Parkinson, Départements de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, UMR 1214 TONIC, NeuroToul and NS-PARK/FCRIN Network, INSERM, CHU de Toulouse et Université de Toulouse3, Toulouse, France.
³² ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS, Toulouse, France.
³³ INRAE, UR QuaPA, 63122, Saint-Genès-Champanelle, France.
³⁴ Nuclear Magnetic Resonance Facility for Agronomy, Food and Health, AgroResonance, INRAE, 2018, Saint-Genès-Champanelle, France.

PMID: 37648911
DOI: 10.1007/s00415-023-11947-0

Abstract

Background: Longitudinal measures of structural brain changes using MRI in relation to clinical features and progression patterns in PD have been assessed in previous studies, but few were conducted in well-defined and large cohorts, including prospective clinical assessments of both motor and non-motor symptoms.

Objective: We aimed to identify brain volumetric changes characterizing PD patients, and determine whether regional brain volumetric characteristics at baseline can predict motor, psycho-behavioral and cognitive evolution at one year in a prospective cohort of PD patients.

Methods: In this multicentric 1 year longitudinal study, PD patients and healthy controls from the MPI-R2* cohort were assessed for demographical, clinical and brain volumetric characteristics. Distinct subgroups of PD patients according to motor, cognitive and psycho-behavioral evolution were identified at the end of follow-up.

Results: One hundred and fifty PD patients and 73 control subjects were included in our analysis. Over one year, there was no significant difference in volume variations between PD and control subjects, regardless of the brain region considered. However, we observed a reduction in posterior cingulate cortex volume at baseline in PD patients with motor deterioration at one year (p = 0.017). We also observed a bilateral reduction of the volume of the amygdala (p = 0.015 and p = 0.041) and hippocampus (p = 0.015 and p = 0.053) at baseline in patients with psycho-behavioral deterioration, regardless of age, dopaminergic treatment and center.

Conclusion: Brain volumetric characteristics at baseline may predict clinical trajectories at 1 year in PD as posterior cingulate cortex atrophy was associated with motor decline, while amygdala and hippocampus atrophy were associated with psycho-behavioral decline.

Keywords: Brain atrophy; Clinical progression; Longitudinal study; Parkinson’s disease; Volumetric changes.

PubMed Disclaimer

References

1. Greenland JC, Williams-Gray CH, Barker RA (2019) The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci 49:328–338. https://doi.org/10.1111/ejn.14094 - DOI - PubMed
1. Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5:355–363. https://doi.org/10.1016/S1474-4422(06)70411-2 - DOI - PubMed
1. Yang J, Burciu RG, Vaillancourt DE (2018) Longitudinal Progression Markers of Parkinson’s Disease: Current View on Structural Imaging. Curr Neurol Neurosci Rep 18:83. https://doi.org/10.1007/s11910-018-0894-7 - DOI - PubMed - PMC
1. McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE (2013) A systematic review of biomarkers for disease progression in Parkinson’s disease. BMC Neurol 13:35. https://doi.org/10.1186/1471-2377-13-35 - DOI - PubMed - PMC
1. Sarasso E, Agosta F, Piramide N, Filippi M (2021) Progression of grey and white matter brain damage in Parkinson’s disease: a critical review of structural MRI literature. J Neurol 268:3144–3179. https://doi.org/10.1007/s00415-020-09863-8 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study

Affiliations

Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical